EVANIUM secures 2.2 million euros for bioavailability of natural substances

The nutraceutical start-up EVANIUM has closed a seed financing round of 2.2 million euros. Investors include FoodLabs, Feast Ventures and several business angels. The new funds will be used for the expansion of the product portfolio, clinical studies and international market expansion.

Technology improves absorption of herbal active ingredients

EVANIUM has addressed the problem that many herbal active ingredients are insufficiently absorbed by the body. With its proprietary OPTISOLV® technology, the company relies on a dual-coating process that significantly improves solubility, stability and bioavailability.

According to the company, the solubility of poorly soluble active ingredients such as curcumin has been increased more than 1,000-fold.

More efficient formulations instead of higher dosages

CEO Felix Rolka emphasizes that the future of the industry does not lie in higher dosages, but in more intelligent formulations.

OPTISOLV transforms promising bioactives into high-performance ingredients, enabling truly effective products.

Felix Rolka, Co-Founder and CEO

The technology should make it possible to develop more powerful ingredients from existing bioactive substances and thus create more effective products.

First market successes and industrial scaling

Last year, EVANIUM launched its first product on the market together with Hevert-Arzneimittel GmbH & Co. KG launched its first product on the market last year. The start-up has now brought four active ingredients to industrial maturity and has already produced and sold more than two tons in 2026.

EVANIUM is also a finalist in the Vitafoods Europe Startup Challenge in the "Most Innovative Nutraceutical Ingredient" category with its product OPTISOLV® Berberine. The company intends to use the fresh capital to further scale up its technology, clinically validate it and establish new partnerships in the nutraceuticals, nutricosmetics and functional food sectors.